Ann: Trading Halt , page-8

Phylogica is one of few companies in the biologics sector that combines a proprietary library of
peptides enriched for drug-like properties, with a powerful screening technology; together
these yield high quality drug leads. We consider it is companies with validated libraries of
potential drugs, rather than technology platform companies, which merely provide enabling
technologies, that are likely to realise the most value from partnering or collaborating with
pharmaceutical companies, even at the preclinical stage.